TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA

Translated title of the contribution: Antilymphocyte globulin therapy for paroxysmal nocturnal hemoglobinuria

E. Sanchez-Valle, M. R. Morales-Polanco, E. Gomez-Morales, L. I. Gutierrez-Alamillo, G. Gutierrez-Espindola, J. Pizzuto-Chavez

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the effectiveness of antilymphocyte globulin therapy (ALG) in patients with paroxysmal nocturnal hemoglobinuria (PNH). Design. Prospective, non-controlled trial. Setting. Hematology Service, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City. Patients. Six patients were included. The median age was 37.5 years and the male/female ratio was 1:1. All the patients had clinical disease consistent with PNH (hemolytic anemia with some degree of transient or persistent pancytopenia) and also erythrocytes with enhanced sensitivity to complement mediated lysis in vitro, as documented by either the Ham test or the sucrose lysis assay. The criterion for severity was the existence of continuous hemolysis in all and transfusion requirements of two or more packed red cells per month in four cases. Prior to ALG therapy, androgens and/or steroids had been given to five patients with no improvement. Intervention. A single batch of ALG was used during the trial (E 0034, Lymphoglobulin Merieux, Lyon, France). Patients received an infusion of 10 mg/kg per day in a 20 hours lapse during four consecutive days. Also 500 mg/day of methylprednisolone were started simultaneously with the ALG; it was given for seven days and was gradually tapered off and stopped on day 30. Measurements. The increases in hemoglobin, granulocytes and/or platelets as well as decreases in red cell transfusion requirements were used to evaluate the results of therapy. Results. Two patients suffered anaphylaxis after the first administration of ALG and were withdrawn from the study. Two of the four remaining patients responded, one response was total and the other minimal. The responses were transient, and no response was seen in the follow-up of 11-14 months. Conclusion. ALG therapy for PNH in the doses and time periods used by us had no beneficial effect in patients with a severe form of PNH.

Translated title of the contributionAntilymphocyte globulin therapy for paroxysmal nocturnal hemoglobinuria
Original languageSpanish
Pages (from-to)457-461
Number of pages5
JournalRevista de Investigacion Clinica
Volume45
Issue number5
StatePublished - Dec 1 1993
Externally publishedYes

Keywords

  • antilymphocyte globulin therapy
  • paroxysmal nocturnal hemoglobinuria

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antilymphocyte globulin therapy for paroxysmal nocturnal hemoglobinuria'. Together they form a unique fingerprint.

  • Cite this

    Sanchez-Valle, E., Morales-Polanco, M. R., Gomez-Morales, E., Gutierrez-Alamillo, L. I., Gutierrez-Espindola, G., & Pizzuto-Chavez, J. (1993). TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA. Revista de Investigacion Clinica, 45(5), 457-461.